Last reviewed · How we verify
Budesonide pMDI
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide pMDI |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a selective glucocorticoid receptor agonist that acts locally in the lungs when delivered via pressurized metered-dose inhaler (pMDI). It inhibits the release of inflammatory cytokines, reduces recruitment of inflammatory cells, and decreases mucus production, thereby reducing airway inflammation and improving airflow obstruction in respiratory conditions.
Approved indications
- Asthma (maintenance and reliever therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Dysphonia
- Throat irritation
Key clinical trials
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |